SCHEMBL223154

SCHEMBL223154

CC(=O)N1c2ccc(N3CCOCC3)cc2[C@@H](O)C[C@@H]1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 4/20 0.48
BRD4 O60885 4/20 0.43
BRD2 P25440 3/20 0.43
BRD3 Q15059 3/20 0.43
MAPT P10636 3/20 0.41
TNF P01375 5/20 0.41
NOD2 Q9HC29 5/20 0.41
NOD1 Q9Y239 5/20 0.41
PIK3CD O00329 2/20 0.40
PIK3CA P42336 2/20 0.40
PIK3CB P42338 2/20 0.40
PIK3CG P48736 2/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 1/20 0.40
KIF11 P52732 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221281 1.00 PRKDC (0.48) PRKDCBRD4BRD2BRD3MAPT
SCHEMBL223665 0.83 BRD4 (0.60) BRD4BRD2BRD3
SCHEMBL5836450 0.81 BRD4 (0.67) BRD4BRD2BRD3
SCHEMBL5836452 0.81 BRD4 (0.67) BRD4BRD2BRD3
SCHEMBL222018 0.80 BRD4 (0.56) BRD4BRD2BRD3
SCHEMBL224960 0.80 BRD4 (0.56) BRD4BRD2BRD3
SCHEMBL224961 0.80 BRD4 (0.56) BRD4BRD2BRD3
SCHEMBL220841 0.79 TNF (0.44) PRKDCBRD4BRD2BRD3MAPT
SCHEMBL224468 0.79 SMN1; SMN2 (0.51) PRKDCBRD4BRD2BRD3MAPT
SCHEMBL224467 0.79 SMN1; SMN2 (0.51) PRKDCBRD4BRD2BRD3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045423-B2 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient KOWA COMPANY, LTD. (JP) 2015-06-02 US disclosed
US-20140249144-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT KOWA COMPANY, LTD. (JP) 2014-09-04 US disclosed
US-8791090-B2 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient KOWA COMPANY, LTD. (JP) 2014-07-29 US disclosed
EP-2415764-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT Kowa Company, Ltd. (JP) 2012-02-08 EP disclosed
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT KOWA COMPANY, LTD. (JP) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249144-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT EPOR, HBG1, HBG2 PRKDC 4864/4885BRD4 861/4885BRD2 1499/4885
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT EPOR, HBG1, HBG2 PRKDC 4864/4885BRD4 861/4885BRD2 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.